Triglycerides and ASCVD risk reduction: Recent insights and future directions
Document Type
Article
Department
Office of the Provost; Cardiology
Abstract
Purpose of review: This review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD). It also provides a succinct overview of current and future TG-lowering therapies for ASCVD risk reduction.
Recent findings: Epidemiological and Mendelian randomization studies have consistently shown that TGRL are strongly associated with ASCVD. REDUCE-IT demonstrated cardiovascular benefit with icosapent ethyl in high-risk patients with hypertriglyceridemia on statin therapy. Polymorphisms in APOC3 and ANGPTL3 are associated with ASCVD and use of RNA-interfering therapies to target these proteins has shown TG lowering in early phase trials. TG and TGRL are causally associated with ASCVD. Lifestyle modifications and statin therapy can lower TG/TGRL and are considered first-line treatment for hypertriglyceridemia. Icosapent ethyl has been shown to reduce residual ASCVD risk in high-risk patients on maximally tolerated statins. Ongoing clinical trials will better define optimal therapy for patients on statins with residual hypertriglyceridemia.
Publication (Name of Journal)
Current Atherosclerosis Reports
DOI
https://doi.org/10.1007/s11883-020-00846-8
Recommended Citation
Hussain, A.,
Ballantyne, C. M.,
Saeed, A.,
Virani, S. S.
(2020). Triglycerides and ASCVD risk reduction: Recent insights and future directions. Current Atherosclerosis Reports, 22(7), 25.
Available at:
https://ecommons.aku.edu/provost_office/587
Comments
Pagination is not provided by the author/publisher. This work was published before the author joined Aga Khan University.